M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 30 of 54
Occupational Therapy in Palliative Care
NCT02521194
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
NCT02394535
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
NCT02529852
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT02420795
Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers
NCT02596711
Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer
NCT02590458
Nivolumab in AML in Remission at High Risk for Relapse
NCT02532231
Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT02405078
Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior
NCT03046524
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
NCT02420613
Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix
NCT02206048
Studying Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid Myopathy
NCT04521777
Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer
NCT02360059
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
NCT02469415
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
NCT02502396
Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia
NCT02420665
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
NCT02385110
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
NCT02441803
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
NCT02506959
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
NCT02459964
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease
NCT02458014
Video Double-Lumen Tube Prospective Randomized Study
NCT02429414
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
NCT02420691
Perception of Palliative Care Encounter
NCT02558257
Edmonton Symptom Assessment Scale: Self-Completion vs. Assisted-Completion
NCT02523378
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
NCT02500576
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
NCT02423915
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
NCT02402920
Registry Study for Personalized Cancer Therapy
NCT02508662
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
NCT02420717
Robotic Harvest of the Latissimus Dorsi (LD) Muscles
NCT02274493
Intratumoral Injections of LL37 for Melanoma
NCT02225366
The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting
NCT02271906
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
NCT02464657
Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients
NCT02321527
Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion
NCT02498899
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
NCT02419495
Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
NCT02481297
Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
NCT02389764
Time From Onset of Fever to Administration of Antibiotics in Neutropenic Fever Patients
NCT03968328
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
NCT02420912
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
NCT02410551
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02316834
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
NCT02169505
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
NCT02293005
Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure
NCT02159872
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
NCT02421354
An Open-label Phase II Study of Lorvotuzumab Mertansine
NCT02420873
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
NCT02141477
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
NCT02286726
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.